Results 141 to 150 of about 93,359 (239)
COPD patients with non-small cell lung cancer respond better to anti-PD-(L)1 immune checkpoint inhibitors. [PDF]
Boudoussier A+9 more
europepmc +1 more source
Abstract Skin flash is typically added to breast and chestwall plans to ensure robust target coverage in the presence of respiratory motion, anatomic changes, and small setup uncertainties. Adding skin flash in volumetric modulated arc therapy (VMAT) plans is an iterative and manual process.
Emily Hubley+6 more
wiley +1 more source
Population-based Screening for Chronic Obstructive Pulmonary Disease Using the St. George's Respiratory Questionnaire in Resource-limited Settings. [PDF]
Checkley W+17 more
europepmc +1 more source
ABSTRACT Background Exposure to the terrorist attacks on the World Trade Center (WTC) on September 11, 2001, has been associated with several chronic physical and mental health conditions. We assessed the burden, nearly 20 years after the attacks, of several 9/11‐related health conditions and indicators of poor health‐related quality of life (HRQOL ...
Julia S. Sisti+5 more
wiley +1 more source
The effect of a post-bronchodilator FEV<sub>1</sub>/FVC < 0.7 on COPD diagnosis and treatment: a regression discontinuity design. [PDF]
Moffett AT, Halpern SD, Weissman GE.
europepmc +1 more source
Determining Thresholds for Computer‐Aided Detection for Silicosis—An Analytic Approach
ABSTRACT Background Computer‐aided detection (CAD) is emerging as an adjunct to the use of the chest X‐ray (CXR) in screening for pulmonary tuberculosis (TB). CAD for silicosis, a fibrotic lung disease due to silica dust and a strong risk factor for TB, is at an earlier stage of development and, unlike TB, depends on expert human reading for validation.
Stephen Barker+4 more
wiley +1 more source
A comparison of pulmonary function pre and post mild SARS-CoV-2 infection among healthy adults. [PDF]
Taib RR+5 more
europepmc +1 more source
Graphical abstract, Venous bicarbonate as a prognostic biomarker and proposed proxy for vital capacity to be used as an eligibility criterion in amyotrophic lateral sclerosis clinical trials. ABSTRACT Background Clinical trials for people living with ALS (pALS) all list vital capacity (VC) as an important eligibility criterion. However, VC measures are
Juliette Foucher+6 more
wiley +1 more source